Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.13 AUD
Change Today +0.015 / 13.64%
Volume 13.3K
As of 12:38 AM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

regeneus ltd (RGS) Snapshot

Open
A$0.12
Previous Close
A$0.11
Day High
A$0.13
Day Low
A$0.12
52 Week High
09/11/14 - A$0.33
52 Week Low
10/7/14 - A$0.10
Market Cap
26.1M
Average Volume 10 Days
214.2K
EPS TTM
A$-0.03
Shares Outstanding
208.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for REGENEUS LTD (RGS)

Related News

No related news articles were found.

regeneus ltd (RGS) Related Businessweek News

No Related Businessweek News Found

regeneus ltd (RGS) Details

Regeneus Ltd, a regenerative medicine company, develops and commercializes stem cell and other biological therapies for the human and veterinary health markets with a focus on musculoskeletal and oncology conditions in Australia. The company provides HiQCell, an autologous adipose derived stem cell therapy for human osteoarthritis and other musculoskeletal conditions. It also offers animal health products comprising CryoShot, an allogeneic cell-based product for use as an intra-articular injection for osteoarthritis, an adjunct to joint surgery, and an intra-lesional injection for tendinopathy in canine and equine markets; and Kvax, an autologous therapeutic cancer vaccine. In addition, the company is developing a stem cell secretions cream for inflammatory skins conditions, such as acne, rosacea, and psoriasis; and Progenza, an allogeneic cell therapy treatment for human osteoarthritis. Regeneus Ltd was founded in 2007 and is headquartered in Pymble, Australia.

Founded in 2007

regeneus ltd (RGS) Top Compensated Officers

Chief Executive Officer, Director, Member of ...
Total Annual Compensation: A$440.5K
Chief Scientific Officer and Executive Direct...
Total Annual Compensation: A$339.5K
Compensation as of Fiscal Year 2014.

regeneus ltd (RGS) Key Developments

Regeneus Ltd. Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2015

Regeneus Ltd. reported audited consolidated earnings results for the year ended June 30, 2015. For the year, the company reported revenue of AUD 2,061,094 against AUD 2,094,643 a year ago. Loss before income tax was AUD 6,606,521 against AUD 7,523,218 a year ago. Loss for the year was AUD 6,606,521 against AUD 7,523,218 a year ago. Basic and diluted loss per share from continuing operations were AUD 0.03 against AUD 0.05 a year ago. Net cash used in operating activities was AUD 5,923,357 against AUD 6,239,251 a year ago. Purchase of property, plant and equipment was AUD 193,017 against AUD 1,174,695 a year ago. Purchase of intangibles was AUD 14,841 against AUD 1,180 a year ago.

Regeneus Ltd expected to report Fiscal Year 2015 results on September 1, 2015. This event was calculated by Capital IQ (Created on August 26, 2015).

Regeneus Ltd expected to report Fiscal Year 2015 results on September 1, 2015. This event was calculated by Capital IQ (Created on August 26, 2015).

Regeneus Ltd Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 04:50 PM

Regeneus Ltd Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015 04:50 PM. Venue: Metropolitan Club, One East 60th Street, New York, NY 10022, United States. Speakers: John Dominic Martin, Chief Executive Officer, Director, Member of Audit & Risk Committee and Member of Remuneration & Nominations Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RGS:AU A$0.13 AUD +0.015

RGS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Orthocell Ltd A$0.56 AUD -0.02
View Industry Companies
 

Industry Analysis

RGS

Industry Average

Valuation RGS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.3x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REGENEUS LTD, please visit www.regeneus.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.